NHS proposes phased launch for Eli Lilly's Mounjaro [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
blockbuster weight loss drug Mounjaro (tirzepatide) because of the large number of patients who could benefit from using it. The proposal was sent by the NHS to the National Institute for Health and Care Excellence (NICE) as the regulator decides how to distribute the treatment. The regulator recommended Mounjaro for those who are obese in June this year. The weekly injection costs £122 per month at its maximum dose of 15g. NICE's chief executive Dr Sam Roberts said: “Because of the very large number of people who could potentially benefit, NICE accepts that a phased rollout is required.” NICE has now opened a consultation period of three weeks to decide exactly how the rollout will work before publishing final guidance later this year, as per a 3 October press release. Mounjaro has made waves in the weight loss space due to its high efficacy, helping improve patient outcomes far more than diet and exercise alone. As a result, demand for the injection exceeded supply during in
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- What end of Eli Lilly's weight-loss drug shortage means for the competition [Yahoo! Finance Canada]Yahoo! Finance Canada
- Eli Lilly's Mounjaro, Zepbound removed from FDA's shortage list [Yahoo! Finance Canada]Yahoo! Finance Canada
- What end of Eli Lilly's weight-loss drug shortage means for the competition [Yahoo! Finance]Yahoo! Finance
- England's NHS Proposes Phased Rollout of Eli Lilly's Mounjaro, Considers Digital Services to Boost Access [Yahoo! Finance]Yahoo! Finance
- Mounjaro, Zepbound shortage eases as supplies of weight loss drug rebound [USA TODAY]USA TODAY
LLY
Earnings
- 8/8/24 - Beat
LLY
Sec Filings
- 9/18/24 - Form 3
- 9/17/24 - Form 4
- 9/17/24 - Form 4
- LLY's page on the SEC website